232 related articles for article (PubMed ID: 37389187)
21. Unraveling Colorectal Cancer and Pan-cancer Immune Heterogeneity and Synthetic Therapy Response Using Cuproptosis and Hypoxia Regulators by Multi-omic Analysis and Experimental Validation.
Jiang PC; Fan J; Zhang CD; Bai MH; Sun QQ; Chen QP; Mao W; Tang BF; Lan HY; Zhou YY; Zhu J
Int J Biol Sci; 2023; 19(11):3526-3543. PubMed ID: 37496994
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
[TBL] [Abstract][Full Text] [Related]
23. Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer.
Zhang H; Liu J; Zheng Z
PeerJ; 2023; 11():e15088. PubMed ID: 37041979
[TBL] [Abstract][Full Text] [Related]
24. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
25. Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis.
Zhang S; Yu S; Duan H; Xia W; Wang C; Shen H
Front Genet; 2022; 13():997573. PubMed ID: 36263417
[No Abstract] [Full Text] [Related]
26. TIGD1 Function as a Potential Cuproptosis Regulator Following a Novel Cuproptosis-Related Gene Risk Signature in Colorectal Cancer.
Wu Z; Lin C; Zhang F; Lu Z; Wang Y; Liu Y; Zhou Z; Li L; Song L
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190215
[TBL] [Abstract][Full Text] [Related]
27. Cuproptosis-related lncRNAs predict the clinical outcome and immune characteristics of hepatocellular carcinoma.
Zhu H; Mao F; Wang K; Feng J; Cheng S
Front Genet; 2022; 13():972212. PubMed ID: 36212138
[TBL] [Abstract][Full Text] [Related]
28. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
29. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma.
Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C
Front Genet; 2023; 14():1124439. PubMed ID: 36936439
[No Abstract] [Full Text] [Related]
30. A novel prognostic signature based on cuproptosis-related lncRNA mining in colorectal cancer.
Hou D; Tan JN; Zhou SN; Yang X; Zhang ZH; Zhong GY; Zhong L; Yang B; Han FH
Front Genet; 2022; 13():969845. PubMed ID: 36105091
[No Abstract] [Full Text] [Related]
31. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
33. A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response.
Ma YL; Yang YF; Wang HC; Yang CC; Yan LJ; Ding ZN; Tian BW; Liu H; Xue JS; Han CL; Tan SY; Hong JG; Yan YC; Mao XC; Wang DX; Li T
Front Pharmacol; 2023; 14():1101749. PubMed ID: 36909185
[No Abstract] [Full Text] [Related]
34. Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma.
Li M; Song Q; Bai Y; Hua F; Wu T; Liu J
Front Pharmacol; 2022; 13():992431. PubMed ID: 36263140
[TBL] [Abstract][Full Text] [Related]
35. Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer.
Zhang E; Ding C; Li S; Aikemu B; Zhou X; Fan X; Sun J; Yang X; Zheng M
Cancer Cell Int; 2023 May; 23(1):96. PubMed ID: 37202800
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Analysis of the Relationship between Cuproptosis-Related Gene GCSH and Prognosis, Tumor Microenvironment Infiltration, and Therapy Response in Endometrial Cancer.
Zhao M; Nie H; Qiu P; Yu Y; Wang H; Wang F; Fang J; Zhao Q
Oncology; 2024; 102(5):368-381. PubMed ID: 37827132
[TBL] [Abstract][Full Text] [Related]
37. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.
Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S
Front Immunol; 2022; 13():945516. PubMed ID: 36248857
[TBL] [Abstract][Full Text] [Related]
38. The characterization of tumor microenvironment infiltration and the construction of predictive index based on cuproptosis-related gene in primary lung adenocarcinoma.
Li K; Wu LL; Wang H; Cheng H; Zhuo HM; Hao Y; Liu ZY; Li CW; Qian JY; Li ZX; Xie D; Chen C
Front Oncol; 2022; 12():1011568. PubMed ID: 36505852
[TBL] [Abstract][Full Text] [Related]
39. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of the cuproptosis-related model to predict prognosis and indicate tumor immune infiltration in lung adenocarcinoma.
Wu M; Bao J; Lei Y; Tao S; Lin Q; Chen L; Jin Y; Ding X; Yan Y; Han P
Front Oncol; 2022; 12():935672. PubMed ID: 36338763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
